Investors in Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA
Portfolio Pulse from
A class action securities lawsuit has been filed against Intellia Therapeutics, alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting NTLA-3001 research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
March 27, 2025 | 5:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia Therapeutics announced discontinuation of NTLA-3001 program and 27% workforce reduction, leading to potential legal action and stock price decline.
The lawsuit and program discontinuation suggest significant operational challenges, potential financial strain, and loss of investor confidence, which could negatively impact NTLA stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100